Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Authors:
- Hans Skovgaard PoulsenHPHans Skovgaard Poulsen
- Kirsten GrunnetKGKirsten Grunnet
- Morten SorensenMSMorten Sorensen
- Preben OlsenPOPreben Olsen
- Benedikte HasselbalchBHBenedikte Hasselbalch
- Knud NelausenKNKnud Nelausen
- Michael KosteljanetzMKMichael Kosteljanetz
- Ulrik LassenULUlrik Lassen
- 1 January 2009
- journal article
- clinical trial
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 48 (1) , 52-58
Abstract
We retrospectively determined the efficacy and safety of a combination of bevacizumab and irinotecan in a consecutive series of 52 heavily pre-treated patients with recurrent high-grade brain tumours. Patients received bevacizumab (10 mg/kg) and irinotecan [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) and 125 mg/m(2) for those not receiving EIAEDs] every 2 weeks. Fifty-two patients were included and 47 were evaluable for response. Complete or partial response was observed in 25% of all cases (30% response in grade IV glioma and 15% in grade III glioma). Estimated median progression-free survival (PFS) for both grade IV and grade III glioma was 22 weeks. The 6-month PFS was 32% for all patients, 40% for grade IV glioma and 33% for grade III glioma. Estimated median overall survival was 30 weeks for all patients, 28 weeks for grade IV glioma and 32 weeks for grade III glioma. Four patients discontinued treatment because of unmanageable toxicity: cerebral haemorrhage, cardiac arrhythmia, intestinal perforation and diarrhoea, the latter resulting in death. We conclude that the combination of bevacizumab and irinotecan shows acceptable safety and is a clinically relevant choice of therapy in heavily pre-treated patients with recurrent high-grade brain tumours.Keywords
This publication has 38 references indexed in Scilit:
- Angiogenesis in brain tumoursNature Reviews Neuroscience, 2007
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional TherapiesCancer Research, 2006
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006
- Recent developments in the use of chemotherapy in brain tumoursEuropean Journal of Cancer, 2006
- Changing Paradigms—An Update on the Multidisciplinary Management of Malignant GliomaThe Oncologist, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsThe Lancet, 2002